The path for a cure or vaccine for HIV is littered with disappointments – much-hyped treatments or trials have ultimately ended in failure.
Today, however, the HIV research community is more hopeful, especially in lieu of PrEP – pre-exposure prophylaxis – the use of the antiretroviral drug Truvada to prevent HIV infection. With PrEP, HIV-negative individuals take a daily dose of Truvada to halt HIV transmission, and the drug is more than 99 percent effective at preventing HIV when taken daily.
Therein, however, lies the rub: PrEP requires daily adherence.
Flush on the heels of PrEP is a major new, multi-continent trial that will test a lab-created antibody to determine if it is effective in preventing HIV transmission.
The antibody was discovered in an HIV-infected individual who was able to control HIV infection without medication. Replicated in a lab, researchers will inject a solution containing the antibody into HIV-negative men and transgender individuals who have sex with men through an IV, then monitor whether infections occur.
The new study is called AMP, for antibody-mediated prevention.
“This is landmark study,” said Shobha Swaminathan, an infectious disease specialist who is part of the study. “It is the first study of this magnitude to see whether an antibody infusion can help prevent new HIV infections. If it proves effective, it could potentially pave a way for developing a vaccine for HIV infection.”
Typically, vaccines introduce a biological agent that stimulates the body’s immune system to recognize and fight off a particular disease. Many vaccines spark the body to create antibodies.
In AMP, patients recruited for the study will receive transfusions of saline solution including the antibody once every eight weeks. The trial will continue for roughly two years.
AMP is not a test for a vaccine. The antibody being studied dissipates over time. The hope, however, is that scientists can find antibodies that prevent HIV from replicating, and eventually create a vaccine that induces the body to produce antibodies that prevent HIV infection.
The study will recruit 2,700 men and transgender individuals whose sexual partners are men. In addition to being offered the antibody IV, participants will be counseled on safer sex practices and offered PrEP. Those already taking PrEP are not ineligible for the study.
The AMP study isn’t the only study looking at options for HIV prevention. Researchers are also currently testing long-lasting injectable medication, also administered about once every two months. The drug currently being tested is called cabotegravir and is owned by ViiV Healthcare. Cabotegravir has performed well in safety studies and animal testing.
Additionally, researchers are currently recruiting participants to test another iteration of Truvada. A study on non-human primates found the drug 100% effective at preventing HIV, but a second study suggested blood levels of the primary HIV-fighting drug in the body might be too low to be effective.
Gilead Sciences, the maker of Truvada, will soon be testing a modified version of the drug that has fewer reported side effects. Results from that study are expected in 2020.
Roughly 45,000 people contract HIV in the United States every year. Worldwide, roughly 37 million people are living with HIV. Most live in sub-Saharan Africa, where many of the AMP test sites are located.
When first recognized in 1981, HIV was usually fatal; today, it can typically be treated – but not cured – with a single daily pill that combines several anti-retroviral drugs.
To find out more about AMP, or to volunteer for the study, visit ampstudy.org.
Republican’s latest anti-Schiff sign hilariously backfires
House Republicans have had a difficult time defending President Donald Trump and his actions on Ukraine. They've tried to pivot to attack the process and claim that somehow Democrats are stacking the deck against the GOP. Unfortunately, however, they can't even do that correctly.
After a lunch break, Republicans in the House Intelligence Committee propped up a sign reading, "Days since Adam Schiff followed the rules 0." That would mean that Chairman Adam Schiff (D-CA) is following the rules today. If Republicans meant to attack Schiff or claim that Democrats were ignoring the House rules it would read a larger number of days, for example, "4 days since Adam Schiff followed House rules."
Trump’s Syria withdrawal was an ‘intelligence and propaganda gift to Russia’: report
In a surprise move last month, President Trump withdrew a contingent of US troops from their posts in northeast Syria, sparking widespread outrage from observers who saw it as yet another betrayal of Kurdish factions who were fighting as allies of the US. According to a report from Business Insider this Thursday, Trump's decision not only undid years of US-led efforts to combat ISIS, it also was an "intelligence (and propaganda) gift to Russia."
Within days of the US withdrawal, Kremlin-funded propaganda outlets were broadcasting from America's abandoned bases in the region while "Russian and other hostile intelligence officials" were mining the facilities "for insights into Western intelligence," Business Insider reports.
Fiona Hill’s impeachment testimony serves as a warning about US election security and the 2020 race
During her bombshell impeachment testimony before members of the House Intelligence Committee on Thursday morning, foreign affairs expert Fiona Hill not only made a strong case for President Donald Trump’s impeachment — she also gave Americans plenty of reason to be concerned about U.S. election security and the 2020 presidential election. Former Special Counsel Robert Mueller, during his public testimony earlier this year, made it abundantly clear that the Russian government under President Vladimir Putin interfered in the 2016 U.S. election and will no doubt interfere in the United States’ 2020 election if it can — and Hill, a former National Security Council (NSC) senior director specializing in Russian and European affairs, gave Americans plenty of reasons to be concerned about next year’s election.